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Introduction
Malaria, a disease caused by Plasmodium species, is
one of the oldest and largest health challenges
affecting 40% of the world’s population1. It affects
300–500 million people and kills 1.5–2.7 million
annually2. WHO forecasts 16% growth in malaria
cases annually. These estimates rank malaria as one
of the top three killers among infectious diseases3.
The increasing incidences of malaria in tropical and
subtropical countries reflect the development of drug
resistant strains of Plasmodium and justify referring
to malaria as a re-emerging disease3–5. Most of the
molecular and biochemical studies have been done
on Plasmodium falciparum, as it is the most deadly
parasite among the four human Plasmodia. Even
though P. vivax is responsible for tremendous
morbidity due to the disease, little is known about
its basic biological processes. P. vivax accounts for
approximately 70–80 million cases annually6. In
India >50% cases of malaria are due to P. vivax7.
Although rarely fatal, it causes debilitating disease
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Abstract
Background & objectives: Plasmodium vivax is geographically widespread and responsible for >
50% of malaria cases in India. Increased drug resistance of the parasite highlights the immediate
requirement of early and accurate diagnosis as well as new therapeutics. In view of this, the present
study was undertaken to amplify P. vivax (Indian strains) lactate dehydrogenase gene (PvLDH)
which has been identified as a good target for antimalarials as well as diagnostics.
Methods: P. vivax infected clinical blood samples were collected from southern part of India and
were tested with established diagnostic parameters (ICT, Giemsa staining). Total DNA was extracted
from blood samples and subjected to PCR using two sets of primers, one for the amplification of full
PvLDH gene (951bp) and the other for a partial PvLDH gene fragment (422bp), covering a variable
antigenic region (140aa) as compared to other plasmodial species.
Results & conclusion: PCRs for both the full and partial gene targets were optimised and found to be
consistent when tested on several P. vivax positive clinical samples. In addition, full gene PCR was
found to specifically detect only P. vivax DNA and could be used as a specific molecular diagnostic
tool. These amplified products can be cloned and expressed as a recombinant protein that might be
useful for the development and screening of antimalarials as well as for diagnostic purposes.
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that severely affects the quality of life and economic
productivity of its victims. P. vivax is of great
importance as it is the most geographically
widespread and is of common occurrence of all
malarial Plasmodia. Early and accurate diagnosis and
development of new antimalarials, whose targets
differ from that of currently used drugs, remain the
only available option in reducing morbidity and
mortality due to malaria in tropical countries.
Plasmodium is homolactate fermenter and depends
extensively upon anaerobic glucose metabolism for
ATP production8. The parasite lactate dehydrogenase
(pLDH), 316 amino acids tetrameric enzyme, is
essential for energy production as it converts pyruvate
to lactate while regenerating NAD+ for continued use
in glycolysis9. It has been previously reported that
pLDH has notable structural and kinetic properties
making it different from mammalian and bacterial
LDH enzymes10,11. It has been identified both as
potential antimalarial drug target and as an indicator
of blood parasitaemia level in diagnosis12,13.
In the present study, we report the amplification of
complete (951bp) as well as partial (422bp)  P. vivax
LDH gene (PvLDH).
Material & Methods
Collection of blood samples: P. vivax infected blood
samples (2–3 ml) were collected in heparinised vials
from southern part of India after testing with Now®
ICT Kit (Binax Inc., USA). Thin and thick blood
smears from each sample were prepared. The slides
were stained with Giemsa stain and examined under
light microscope to confirm P.  vivax infection and
to estimate parasitaemia level. The samples were
stored at 4oC till further use. Clinical samples for
the study were collected after obtaining prior
permission from the authorities and informed
consents from the patients.
Isolation of P. vivax genomic DNA:  Vials containing
blood samples were centrifuged at 1500 rpm for 10
min. Plasma and buffy coat of leucocytes were
removed  and RBCs (200 m l) were processed for the
isolation of Pv genomic DNA by using a QIAamp®
DNA Blood Mini Kit (Qiagen, Valencia, CA) as per
manufacturer’s instructions. For each DNA sample,
absorbance at 260 nm was measured and DNA
concentration calculated as A260 x 50 (µg/ml) x
dilution factor. The integrity of DNA samples was
monitored by agarose gel electrophoresis.
Amplification of PvLDH gene: Based on the partial
LDH gene sequence of P. vivax strain Salvador I
(GenBank accession no. AY486060), oligonucleotide
primers NG3F-(5’TTGAACGTCTGCCCGAGA-
GAT3’) and NG4R (5’GCAACTGCCTCGTC-
GAAC-TT3’) were designed to amplify truncated
region (422 bp/140aa) containing variable antigenic
region as compared with P. falciparum (Fig. 1a).
Antigenicity of PvLDH was determined using
software DNAstar Protean, WI (Fig. 1b). For the
amplification of complete PvLDH gene (951bp)
specific primers NG1F (5’ATGACGCCGAAACCC-
AAAAT3’) and NG2R (5’TTAAATGAGCGCCTT-
CATCC3’) were constructed based on the sequence
of PvLDH Belem strain (GenBank accession no.
 DQ060151)14.
All reactions were performed in 25 m l reaction
volume using a thermal cycler (Applied Biosystems
Ltd., USA). Reaction mixture used for the complete
as well as partial gene amplification contained 1 x
PCR buffer supplied with the enzyme (MBI Fermentas
Inc., USA), 1.25 mM MgCl2, 200 m M of dNTPs mix,
10 pmol of each primer, 50 ng of Pv genomic DNA
and 1.25 units of Taq Polymerase. PCR programme
was optimised to comprise an  initial denaturation
of 5 min at 94oC, followed by 35 cycles of  94oC for
1 min, 60oC for 1 min and 72oC for 1.5 min, with a
final extension step at 72oC for 10 min.
Prior to the amplification conditions described over
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were optimised to give reliable and reproducible
results. Particularly MgCl2 concentration (1.25–2.25
mM) and annealing temperature (50–60oC) gradients
were used to determine the optimum conditions
under which only the specific amplicon was
produced. While optimisation, all the reaction
components were kept constant except one variable
at a time.
Analysis of PCR products: PCR amplified products
were resolved on 1% agarose gel containing 0.5
mg/ml of ethidium bromide. The bands were
visualised under UV light and documented using
Alpha Innotech imaging system (San Leandro, CA).
Results
A total of 20 clinical samples were examined by
microscopy of Giemsa stained blood smears. Of
these 17 cases  were  having P. vivax infection. Three
cases were positive for P. falciparum. Parasitaemia
level was found to vary between 500 and 5000
parasites/µl. Genomic DNA extracted from different
clinical samples was found to be intact by agarose
gel electrophoresis (Fig. 2, few representatives
shown). The yield of DNA obtained ranged from
1.5 to 3.0 µg. For PCR amplification, DNA isolated
from an individual clinical sample was used as
template. Fig. 1a shows the schematic diagram of
316aa long PvLDH showing the primers used and
variable residues (31aas, vertical lines) of PvLDH
as compared to PfLDH. Multiple attempts to amplify
the complete PvLDH gene by primers based on the
PfLDH gene were unsuccessful. Full gene primers
NG1F, NG2R designed based on the sequence of
PvLDH Belem strain, yielded the PCR product of
expected size (951bp) and thus allowed the
amplification of complete LDH gene (Fig. 3a).
Primers NG3F–NG4R allowed the amplification of
specific antigenic truncated region of PvLDH giving
the product of 422bp (Fig. 3b). The basic conditions
for the amplification reaction were optimised for each
primer set with regard to temperature of annealing
and magnesium chloride concentration. Annealing
temperature of 60oC gave best amplification for both
sets of primers without any additional artefacts (Fig.
4a). The optimum concentration of MgCl2 in the
amplification of complete as well as partial LDH
gene was found to be 1.25 mM (Fig. 4b). The
optimised PCRs were tested on all PvDNA taken for
the study and found to be reproducible. The
Fig. 1:(a) 316 amino acids long PvLDH showing 31 variable residues (vertical lines)  as compared to
PfLDH and the primers used;  and (b) Antigenicity plot of corresponding regions of PvLDH
Fig. 2: Ethidium bromide stained gel of genomic
DNA extracted from different clinical
samples (Lane 1–10). 4 µl of genomic DNA
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specificity of NG1F and NG2R primers was
established by cross-checking on PfDNA and human
DNA. No amplification was obtained in any of these
reactions.
Discussion
Parasitic enzymes, besides having a role in chemo-
therapy, have also been shown as a potential
diagnostic antigens. PfLDH has long been exploited
for both purposes15,16. However, such studies have
not been carried out with PvLDH. In the present
study, we report the amplification of complete
PvLDH gene from Indian strains of P. vivax. The
amplified product has the potential to be expressed
as recombinant protein that can be exploited for the
screening as well as developing new antimalarials
taking PvLDH as a target. It is worth noting that
NG1F, NG2R primers did not show any
amplification with P. falciparum and human DNA.
Fig. 3:  (a) Amplified complete PvLDH gene (951bp). Ladder (Lane 1), Blank
(Lane 2) P. vivax (Lane 3),  P. falciparum (Lane 4),  Human DNA
(Lane 5); and (b)  Amplified partial PvLDH gene (422bp). Ladder
(Lane 1), Blank (Lane 2),  P. vivax (Lane 3)
Fig. 4: Effect of primer/template annealing temperature (a) and  MgCl2 concentration (b) on
amplification of complete  PvLDH gene (951bp)
Annealing Temp (oC) MgCl2 Conc. (mM)
(a) (b)
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A specific PCR product was only obtained when
DNA from the corresponding species was present
in the reaction. Thus, these primers were very
specific to PvLDH and did not cross react with P.
falciparum or human DNA. Hence, the primers
NG1F and NG2R could be used to specifically
detect P. vivax by PCR.  However, its diagnostic
potential could only be ascertained if evaluated onto
a large number of samples. As most of the rapid
diagnostic systems available in the market can only
differentiate between falciparum and non-
falciparum malaria17, a P. vivax specific detection
system is essentially required. For this purpose,
amplification of 422bp region of PvLDH  was
attempted and successfully accomplished. This
aspect could be further elaborated by cloning and
expression of the amplified gene fragment and its
utilisation as a potential antigenic recombinant
protein for the detection of  Pv infections.
In conclusion, we have reported here the
amplification of PvLDH gene from Indian isolates.
Both standardised PCRs were found to be highly
reproducible and gave the desired amplification with
all P. vivax positive clinical samples screened.
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